MedPath

Vorsetuzumab mafodotin

Generic Name
Vorsetuzumab mafodotin
Drug Type
Biotech
CAS Number
1165741-01-4
Unique Ingredient Identifier
699619YVTQ

Overview

Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).

Background

Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath